M. Tanaka
- Oncology top 10%
- Colorectal Cancer Treatments and Studies 4
- Cancer Cells and Metastasis 3
- Peptidase Inhibition and Analysis 3
- HER2/EGFR in Cancer Research 2
- Orthodontics top 10%
- Complementary and Manual Therapy top 10%
- Temporomandibular Joint Disorders 2
-
- Gastric Cancer Management and Outcomes 5
-
- Glycosylation and Glycoproteins Research 3
- Biochemical and Molecular Research 2
M. Tanaka
35 papers receiving 681 citations
Peers
Comparison fields: 5 of 100
- Oncology 306
- Orthodontics 34
- Complementary and Manual Therapy 13
- Radiology, Nuclear Medicine and Imaging 133
- Pulmonary and Respiratory Medicine 178
Countries citing papers authored by M. Tanaka
This map shows the geographic impact of M. Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Tanaka more than expected).
Fields of papers citing papers by M. Tanaka
This network shows the impact of papers produced by M. Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Tanaka. The network helps show where M. Tanaka may publish in the future.
Co-authorship network
The 25 scholars most cited alongside M. Tanaka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 14 | |
| 2 | 2012 | 24 | |
| 3 | Tele-care system for man and machine in isolated island | 2010 | 1 |
| 4 | 2010 | 12 | |
| 5 | The Efficacy of FK506 Eye–Drop in the Treatment of Ocular Surface Complications in Patients With Severe Allergic Patients With Corneal Complications | 2005 | 1 |
| 6 | 2004 | 1 | |
| 7 | 2003 | 4 | |
| 8 | 2003 | 7 | |
| 9 | 2001 | 16 | |
| 10 | 2001 | 6 | |
| 11 | 1997 | 4 | |
| 12 | 1995 | 6 | |
| 13 | 1995 | 39 | |
| 14 | 1993 | 16 | |
| 15 | 1993 | 6 | |
| 16 | 1993 | 1 | |
| 17 | 1992 | 12 | |
| 18 | 1992 | 25 | |
| 19 | 1992 | 8 | |
| 20 | Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. | 1991 | 270 |
About M. Tanaka
M. Tanaka is a scholar working on Complementary and Manual Therapy, Oncology and Orthodontics, having authored 37 papers that have together received 712 indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Glycosylation and Glycoproteins Research (3 papers), Cancer Cells and Metastasis (3 papers), Peptidase Inhibition and Analysis (3 papers), Biochemical and Molecular Research (2 papers), HER2/EGFR in Cancer Research (2 papers) and Temporomandibular Joint Disorders (2 papers). The work is most often cited by research in Oncology (306 citations), Orthodontics (34 citations) and Complementary and Manual Therapy (13 citations). M. Tanaka has collaborated with scholars based in Japan, United States and Germany. Frequent co-authors include Takamitsu Sasaki, I Miyazaki, Atsushi Ueda, Susumu Nagai, Yasuyuki Agari, Itasu Ninomiya, Yoshio Endou, Sachio Fushida, Hideharu Kimura and Yutaka Yonemura. Their work appears in journals such as Journal of the American Chemical Society, Oncogene and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.